Alterações moleculares em síndrome mielodisplásica

Detalhes bibliográficos
Autor(a) principal: Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP]
Data de Publicação: 2006
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1590/S1516-84842006000300007
http://repositorio.unifesp.br/handle/11600/3229
Resumo: Myelodysplastic syndrome (MDS) is a heterogenous group of clonal hematopoietic disorders. Chromosomal abnormalities detected in this disease were the start to many studies in order to characterize molecular pathogenesis. The loss of genetic material observed in most patients with MDS leads to the hypothesis of tumor suppressor genes (TSG), but this theory does not explain the initial event that underlies growth advantage of hematopoietic progenitor cells, though, different mechanisms are involved such as oncogene activation, altered signaling components and transcription factors. Oncogene mutations, such as RAS, P53, PDGF, FLT3 and MLL, for instance, may contribute to the development of MDS. Tandem mutation of FLT3 is a genetic event that occurs late in the course of the disease and these patients tend to present unfavorable prognosis and imminent transformation into acute myeloid leukemia. Quantitative as well as qualitative abnormalities of transcription factors are detected in MDS and induce the unbalance or block in the differentiation of hematopoietic cells, that results in ineffective hematopoiesis. Epigenentic alterations are characterized by DNA methylation that exerts a role in controlling genic expression. Hypermethylation and inactivation of regulating genes act in the development of the disease. There is a high risk of MDS when p15INK4B is inactivated due to hypermethylation of its promoter. Telomere shortening correlates with complex karyotypes indicating genomic instability and poor prognosis.
id UFSP_604de66c60072e204a6262c058b69354
oai_identifier_str oai:repositorio.unifesp.br/:11600/3229
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Alterações moleculares em síndrome mielodisplásicaMolecular abnormalities in myelodysplastic syndromeChromosomemyelodysplasic syndromeFISHPCRprognosisFLT3LOHSíndrome mielodisplásicaprognósticoFISHFLT3LOHMyelodysplastic syndrome (MDS) is a heterogenous group of clonal hematopoietic disorders. Chromosomal abnormalities detected in this disease were the start to many studies in order to characterize molecular pathogenesis. The loss of genetic material observed in most patients with MDS leads to the hypothesis of tumor suppressor genes (TSG), but this theory does not explain the initial event that underlies growth advantage of hematopoietic progenitor cells, though, different mechanisms are involved such as oncogene activation, altered signaling components and transcription factors. Oncogene mutations, such as RAS, P53, PDGF, FLT3 and MLL, for instance, may contribute to the development of MDS. Tandem mutation of FLT3 is a genetic event that occurs late in the course of the disease and these patients tend to present unfavorable prognosis and imminent transformation into acute myeloid leukemia. Quantitative as well as qualitative abnormalities of transcription factors are detected in MDS and induce the unbalance or block in the differentiation of hematopoietic cells, that results in ineffective hematopoiesis. Epigenentic alterations are characterized by DNA methylation that exerts a role in controlling genic expression. Hypermethylation and inactivation of regulating genes act in the development of the disease. There is a high risk of MDS when p15INK4B is inactivated due to hypermethylation of its promoter. Telomere shortening correlates with complex karyotypes indicating genomic instability and poor prognosis.A síndrome mielodisplásica (SMD) representa um grupo heterogêneo de doenças hematopoéticas clonais. As alterações cromossômicas observadas em SMD foram o ponto de partida para uma série de estudos para a caracterização da patogênese molecular nessa doença. A perda de material genético leva à hipótese de inativação de genes supressores tumorais (GST), mas essa teoria não explica o evento inicial desencadeador da vantagem de crescimento das células progenitoras hematopoéticas, estando outros mecanismos envolvidos, dos quais sobressaem a ativação de oncogenes, alteração de vias de sinalização e fatores de transcrição. Mutações de oncogenes, como RAS, P53, PDGF, FLT3 e MLL, dentre outros, podem contribuir para o desenvolvimento da SMD. A mutação em tandem do FLT3 é evento genético tardio no curso da doença e os pacientes portadores da mesma tendem a apresentar prognóstico desfavorável e transformação iminente para leucemia aguda. Tanto aberrações qualitativas como quantitativas de fatores de transcrição induzem o desequilíbrio ou bloqueio de diferenciação da célula hematopoética, que, por sua vez, se traduz em hematopoese ineficaz. Alterações epigenéticas são caracterizadas por metilação de DNA que tem papel no controle da expressão gênica. Hipermetilação e inativação de genes reguladores exercem função no desenvolvimento da doença. SMD de alto risco está associada à elevada prevalência de inativação do gene supressor tumoral p15INK4B por hipermetilação do promotor. Encurtamento do telômero correlaciona-se a cariótipos complexos, indicando instabilidade genômica e pior prognóstico.UNIFESP-EPM Disciplina de HematologiaFleury-Centro de Medicina DiagnósticaUNIFESP, EPM, Disciplina de HematologiaSciELOAssociação Brasileira de Hematologia e Hemoterapia e Terapia CelularUniversidade Federal de São Paulo (UNIFESP)Fleury-Centro de Medicina DiagnósticaChauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP]2015-06-14T13:36:25Z2015-06-14T13:36:25Z2006-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion188-193application/pdfhttp://dx.doi.org/10.1590/S1516-84842006000300007Revista Brasileira de Hematologia e Hemoterapia. Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, v. 28, n. 3, p. 188-193, 2006.10.1590/S1516-84842006000300007S1516-84842006000300007.pdf1516-8484S1516-84842006000300007http://repositorio.unifesp.br/handle/11600/3229porRevista Brasileira de Hematologia e Hemoterapiainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-07-30T01:54:26Zoai:repositorio.unifesp.br/:11600/3229Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-07-30T01:54:26Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Alterações moleculares em síndrome mielodisplásica
Molecular abnormalities in myelodysplastic syndrome
title Alterações moleculares em síndrome mielodisplásica
spellingShingle Alterações moleculares em síndrome mielodisplásica
Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP]
Chromosome
myelodysplasic syndrome
FISH
PCR
prognosis
FLT3
LOH
Síndrome mielodisplásica
prognóstico
FISH
FLT3
LOH
title_short Alterações moleculares em síndrome mielodisplásica
title_full Alterações moleculares em síndrome mielodisplásica
title_fullStr Alterações moleculares em síndrome mielodisplásica
title_full_unstemmed Alterações moleculares em síndrome mielodisplásica
title_sort Alterações moleculares em síndrome mielodisplásica
author Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP]
author_facet Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP]
author_role author
dc.contributor.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
Fleury-Centro de Medicina Diagnóstica
dc.contributor.author.fl_str_mv Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP]
dc.subject.por.fl_str_mv Chromosome
myelodysplasic syndrome
FISH
PCR
prognosis
FLT3
LOH
Síndrome mielodisplásica
prognóstico
FISH
FLT3
LOH
topic Chromosome
myelodysplasic syndrome
FISH
PCR
prognosis
FLT3
LOH
Síndrome mielodisplásica
prognóstico
FISH
FLT3
LOH
description Myelodysplastic syndrome (MDS) is a heterogenous group of clonal hematopoietic disorders. Chromosomal abnormalities detected in this disease were the start to many studies in order to characterize molecular pathogenesis. The loss of genetic material observed in most patients with MDS leads to the hypothesis of tumor suppressor genes (TSG), but this theory does not explain the initial event that underlies growth advantage of hematopoietic progenitor cells, though, different mechanisms are involved such as oncogene activation, altered signaling components and transcription factors. Oncogene mutations, such as RAS, P53, PDGF, FLT3 and MLL, for instance, may contribute to the development of MDS. Tandem mutation of FLT3 is a genetic event that occurs late in the course of the disease and these patients tend to present unfavorable prognosis and imminent transformation into acute myeloid leukemia. Quantitative as well as qualitative abnormalities of transcription factors are detected in MDS and induce the unbalance or block in the differentiation of hematopoietic cells, that results in ineffective hematopoiesis. Epigenentic alterations are characterized by DNA methylation that exerts a role in controlling genic expression. Hypermethylation and inactivation of regulating genes act in the development of the disease. There is a high risk of MDS when p15INK4B is inactivated due to hypermethylation of its promoter. Telomere shortening correlates with complex karyotypes indicating genomic instability and poor prognosis.
publishDate 2006
dc.date.none.fl_str_mv 2006-09-01
2015-06-14T13:36:25Z
2015-06-14T13:36:25Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/S1516-84842006000300007
Revista Brasileira de Hematologia e Hemoterapia. Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, v. 28, n. 3, p. 188-193, 2006.
10.1590/S1516-84842006000300007
S1516-84842006000300007.pdf
1516-8484
S1516-84842006000300007
http://repositorio.unifesp.br/handle/11600/3229
url http://dx.doi.org/10.1590/S1516-84842006000300007
http://repositorio.unifesp.br/handle/11600/3229
identifier_str_mv Revista Brasileira de Hematologia e Hemoterapia. Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, v. 28, n. 3, p. 188-193, 2006.
10.1590/S1516-84842006000300007
S1516-84842006000300007.pdf
1516-8484
S1516-84842006000300007
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv Revista Brasileira de Hematologia e Hemoterapia
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 188-193
application/pdf
dc.publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268421486936064